5 U/mL was an independent prognostic factor for overall survival (HR 0.34, 95% CI, 0.13-0.85, P=0.0216) (Table 5). Table 5 Multivariate analysis for overall survival Discussion The majority of patients with pancreatic cancer present with unresectable disease and appropriate selection of patients for CRT continues to be a challenge and the treatment of LAPC continues to evolve. Analysis of prognostic factors may be useful in determining which patients would benefit from intensification of therapy and Inhibitors,research,lifescience,medical designing future clinical trials. CA 19-9 is the most common and important tumor marker used in for patients with pancreatic cancer. There have been many

studies evaluating CA 19-9 as prognostic for resectable pancreatic cancer. RTOG 9704 demonstrated a prognostic role for postoperative CA 19-9 in patients with resectable pancreatic carcinoma following surgery. With a post-resection CA 19-9 higher than 90 U/mL, patients had a highly significant increased risk of death Inhibitors,research,lifescience,medical (HR, 3.34; P<0.0001) compared Inhibitors,research,lifescience,medical with those with a value less

than or equal to that cutoff. This was the most important predictor of death in this cohort of patients. The results of this analysis of postoperative CA 19-9 level are important because they clearly identify a subgroup of patients who have a much higher risk of death after surgery with curative intent. In patients receiving systemic chemotherapy for metastatic disease as well as LAPC, CA 19-9 levels have also been shown to be of prognostic significance in terms of overall survival. Tsavaris et al. demonstrated through multivariate Inhibitors,research,lifescience,medical analysis

CA 19-9 levels of >30 times the normal limit had a significant independent effect on survival (5). Serum CA 19-9 alterations have been defined in a number of ways. In a study by Takahashi et al., they developed a new classification Inhibitors,research,lifescience,medical utilizing http://www.selleckchem.com/products/kpt-330.html pretreatment CA 19-9 and proportional alteration of CA 19-9 2 months after the initiation of treatment (14) Their categories were defined as: I (increased), MD (modestly decreased), and SD (substantially decreased). In a study by Halm et al., a decrease of CA 19-9 during chemotherapy with gemcitabine predicted overall survival time in patients with advanced pancreatic cancer (8). In their study, they found that a decrease in CA 19-9 of >20% had the greatest prognostic impact. There is limited data identifying CA 19-9 AV-951 as a prognostic factor in patients with LAPC treated with concurrent CRT as the primary therapy (10-11). In a study by Micke et al. patients with LAPC were treated with hyperfractionated accelerated radiotherapy to a total dose of 44.8 Gy combined with 5-fluorouracil and folinic acid. Patients with a pretreatment CA 19-9 less than the median of 420 U/mL had a new post better median survival versus those with levels greater than the median (12.3 vs. 7.1 months, P=0.0056) (10).